Perrigo Outlines 2025 Growth Plans, Projects Sales Boost And Margin Expansion By 2027
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 28 2025
0mins
Source: Benzinga
Financial Projections: Perrigo Company plc's shares rose significantly after announcing financial targets for 2025, including expected sales growth of 1% to 3%, adjusted EPS of $2.90 – $3.10, and a strategy focused on stabilizing, streamlining, and strengthening its operations.
Recent Performance: The company reported fourth-quarter adjusted EPS of $0.93, slightly below estimates, with sales of $1.14 billion also falling short of expectations; however, the stock price increased by 21.3% following the announcements.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRGO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRGO
Wall Street analysts forecast PRGO stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 10.800
Low
18.00
Averages
20.33
High
23.00
Current: 10.800
Low
18.00
Averages
20.33
High
23.00
About PRGO
Perrigo Company plc is a pure-play self-care company. The Company provides health and wellness solutions. Its segments include Self Care, Specialty Care, and Infant Formula. Self Care comprises Upper Respiratory, Digestive Health, Pain & Sleep and Healthy Lifestyle product categories globally. Specialty Care comprises our Women's Health and Skin Health product categories globally. Infant Formula comprises the Infant Formula product category, which includes nutritional products designed to meet the dietary needs of infants. It provides a store-branded private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill and Mederma. Its Europe portfolio consists primarily of brands, including Compeed, ellaOne, Solpadeine, Jungle Formula, and ACO. Its upper respiratory products include Nasonex 24HR Energy, Mucus DM, All Day Allergy, Nighttime Cold & Flu, and Allergy Relief.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Perrigo to Present at Oppenheimer Consumer Growth Conference
- Conference Schedule: Perrigo's President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are set to present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference on June 9 at 10:30 AM EDT, highlighting the company's latest developments in consumer health.
- Webcast Access: Interested parties can access the conference webcast on Perrigo's official website, providing insights into the company's strategic direction and market performance, thereby enhancing investor confidence.
- Company Background: Perrigo is a leading pure-play consumer health company with over a century of experience focused on delivering high-quality health and wellness solutions primarily to consumers in North America and Europe, ensuring accessibility and choice in the self-care market.
- Business Model: Perrigo's unique business model leverages complementary businesses, where cash-generative store brand private label offerings fuel investments in leading brands such as Opill®, Mederma®, and Compeed®, enhancing its competitive position in the market.
See More
Perrigo Q1 Earnings Beat Expectations Despite Revenue Decline
- Earnings Beat: Perrigo reported a Q1 non-GAAP EPS of $0.43, exceeding expectations by $0.12, indicating resilience in profitability despite revenue challenges.
- Significant Revenue Decline: The company’s revenue of $969 million fell 6.8% year-over-year, missing estimates by $71 million, reflecting intensified market competition and weak demand that could impact future market share.
- Core Sales Pressure: Core net sales were $842 million, down 8.3% year-over-year, with core organic net sales decreasing by 11.0%, highlighting the need for strategic adjustments in product lines and market approach to combat ongoing sales pressures.
- Unchanged Full-Year Outlook: Despite these challenges, Perrigo maintains its full-year 2026 outlook with expectations for improvement in the second half, demonstrating management's confidence in a potential market recovery.
See More
Perrigo Reports Q1 2026 Financial Results Amid Challenges
- Sales Decline: Perrigo's net sales for Q1 2026 were $969 million, a 7.2% decrease year-over-year, primarily due to weakened consumption in the U.S. and Europe, particularly affecting upper respiratory and pain relief products, indicating significant competitive pressure on the company.
- Margin Compression: The reported gross margin was 33.6%, down 400 basis points from the previous year, reflecting the dual pressures of rising production costs and declining sales volumes, which adversely impacted the company's overall profitability.
- Adjusted EPS Drop: The adjusted earnings per share stood at $0.43, a 28.3% decline year-over-year, highlighting challenges in profitability despite management's optimistic outlook for the second half of the year.
- Strategic Restructuring: Perrigo is implementing its
See More
Perrigo Reports Q1 Sales Decline Amid Strategic Changes
- Sales Decline: Perrigo reported net sales of $969 million for Q1, a 7.2% year-over-year decline primarily due to reduced consumption in the U.S. and Europe, particularly from lower seasonal incidence of cough and cold, impacting overall performance.
- Margin Compression: The reported gross margin was 33.6%, down 400 basis points from the previous year, primarily due to decreased sales volumes in the Self Care segment and prior-year manufacturing volume headwinds, indicating challenges in cost management.
- Increased Operating Loss: The company reported an operating loss of $372.3 million for the first quarter, largely driven by a $330.8 million goodwill impairment charge, reflecting significant financial pressure during the transformation process.
- Strategic Adjustments and Outlook: Despite challenges, Perrigo maintains its full-year 2026 outlook, expecting benefits in the second half from previously stated growth initiatives and the Operational Enhancement Program, demonstrating confidence in future performance.
See More
Perrigo Set to Announce Q1 Earnings Results
- Earnings Announcement: Perrigo (PRGO) is set to release its Q1 earnings on May 6 before market open, with consensus EPS estimate at $0.31, reflecting a 48.3% year-over-year decline, while revenue is expected to remain flat at $1.04 billion, indicating challenges in profitability.
- Performance Expectations: Over the past two years, Perrigo has beaten EPS estimates 63% of the time, but only 38% for revenue, suggesting instability in revenue growth that could impact investor confidence.
- Revision Trends: In the last three months, there have been no upward revisions for EPS estimates and one downward revision, while revenue estimates also saw no upward revisions and one downward, reflecting a cautious market outlook on Perrigo's future performance, potentially leading to stock price volatility.
- Market Dynamics: Perrigo has gained attention amid takeover speculation, and although the FDA has confirmed the safety of U.S. baby formula supplies, such speculation may influence investor perceptions of the company's future growth prospects.
See More
Perrigo Completes Sale of Dermacosmetics Business for €332.6 Million
- Significant Transaction Value: Perrigo has completed the sale of its Dermacosmetics business to Karo Healthcare for a total consideration of up to €332.6 million, which includes €305.6 million in upfront cash and an additional €27 million contingent on sales milestones, reflecting the company's proactive asset disposal strategy.
- Enhanced Financial Flexibility: The net proceeds from this transaction are expected to primarily reduce debt, thereby enhancing the company's financial flexibility and improving its balance sheet to support sustainable growth in the future.
- Brand Impact: The brands sold include ACO, Biodermal, Emolium, and Iwostin, with the Dermacosmetics business generating approximately €120 million in net sales in 2025, representing about 5% of Perrigo's adjusted operating income, highlighting the significance of this business in the company's overall strategy.
- Strategic Plan Advancement: CEO Patrick Lockwood-Taylor stated that this transaction marks an important milestone in the execution of the company's Three-S plan, which aims to stabilize, streamline, and strengthen the company by sharpening its focus on core categories and enhancing competitive advantages.
See More
Perrigo to Present at Oppenheimer Consumer Growth Conference
- Conference Schedule: Perrigo's President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are set to present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference on June 9 at 10:30 AM EDT, highlighting the company's latest developments in consumer health.
- Webcast Access: Interested parties can access the conference webcast on Perrigo's official website, providing insights into the company's strategic direction and market performance, thereby enhancing investor confidence.
- Company Background: Perrigo is a leading pure-play consumer health company with over a century of experience focused on delivering high-quality health and wellness solutions primarily to consumers in North America and Europe, ensuring accessibility and choice in the self-care market.
- Business Model: Perrigo's unique business model leverages complementary businesses, where cash-generative store brand private label offerings fuel investments in leading brands such as Opill®, Mederma®, and Compeed®, enhancing its competitive position in the market.
See More
Perrigo Q1 Earnings Beat Expectations Despite Revenue Decline
- Earnings Beat: Perrigo reported a Q1 non-GAAP EPS of $0.43, exceeding expectations by $0.12, indicating resilience in profitability despite revenue challenges.
- Significant Revenue Decline: The company’s revenue of $969 million fell 6.8% year-over-year, missing estimates by $71 million, reflecting intensified market competition and weak demand that could impact future market share.
- Core Sales Pressure: Core net sales were $842 million, down 8.3% year-over-year, with core organic net sales decreasing by 11.0%, highlighting the need for strategic adjustments in product lines and market approach to combat ongoing sales pressures.
- Unchanged Full-Year Outlook: Despite these challenges, Perrigo maintains its full-year 2026 outlook with expectations for improvement in the second half, demonstrating management's confidence in a potential market recovery.
See More
Perrigo Reports Q1 2026 Financial Results Amid Challenges
- Sales Decline: Perrigo's net sales for Q1 2026 were $969 million, a 7.2% decrease year-over-year, primarily due to weakened consumption in the U.S. and Europe, particularly affecting upper respiratory and pain relief products, indicating significant competitive pressure on the company.
- Margin Compression: The reported gross margin was 33.6%, down 400 basis points from the previous year, reflecting the dual pressures of rising production costs and declining sales volumes, which adversely impacted the company's overall profitability.
- Adjusted EPS Drop: The adjusted earnings per share stood at $0.43, a 28.3% decline year-over-year, highlighting challenges in profitability despite management's optimistic outlook for the second half of the year.
- Strategic Restructuring: Perrigo is implementing its
See More
Perrigo Reports Q1 Sales Decline Amid Strategic Changes
- Sales Decline: Perrigo reported net sales of $969 million for Q1, a 7.2% year-over-year decline primarily due to reduced consumption in the U.S. and Europe, particularly from lower seasonal incidence of cough and cold, impacting overall performance.
- Margin Compression: The reported gross margin was 33.6%, down 400 basis points from the previous year, primarily due to decreased sales volumes in the Self Care segment and prior-year manufacturing volume headwinds, indicating challenges in cost management.
- Increased Operating Loss: The company reported an operating loss of $372.3 million for the first quarter, largely driven by a $330.8 million goodwill impairment charge, reflecting significant financial pressure during the transformation process.
- Strategic Adjustments and Outlook: Despite challenges, Perrigo maintains its full-year 2026 outlook, expecting benefits in the second half from previously stated growth initiatives and the Operational Enhancement Program, demonstrating confidence in future performance.
See More
Perrigo Set to Announce Q1 Earnings Results
- Earnings Announcement: Perrigo (PRGO) is set to release its Q1 earnings on May 6 before market open, with consensus EPS estimate at $0.31, reflecting a 48.3% year-over-year decline, while revenue is expected to remain flat at $1.04 billion, indicating challenges in profitability.
- Performance Expectations: Over the past two years, Perrigo has beaten EPS estimates 63% of the time, but only 38% for revenue, suggesting instability in revenue growth that could impact investor confidence.
- Revision Trends: In the last three months, there have been no upward revisions for EPS estimates and one downward revision, while revenue estimates also saw no upward revisions and one downward, reflecting a cautious market outlook on Perrigo's future performance, potentially leading to stock price volatility.
- Market Dynamics: Perrigo has gained attention amid takeover speculation, and although the FDA has confirmed the safety of U.S. baby formula supplies, such speculation may influence investor perceptions of the company's future growth prospects.
See More
Perrigo Completes Sale of Dermacosmetics Business for €332.6 Million
- Significant Transaction Value: Perrigo has completed the sale of its Dermacosmetics business to Karo Healthcare for a total consideration of up to €332.6 million, which includes €305.6 million in upfront cash and an additional €27 million contingent on sales milestones, reflecting the company's proactive asset disposal strategy.
- Enhanced Financial Flexibility: The net proceeds from this transaction are expected to primarily reduce debt, thereby enhancing the company's financial flexibility and improving its balance sheet to support sustainable growth in the future.
- Brand Impact: The brands sold include ACO, Biodermal, Emolium, and Iwostin, with the Dermacosmetics business generating approximately €120 million in net sales in 2025, representing about 5% of Perrigo's adjusted operating income, highlighting the significance of this business in the company's overall strategy.
- Strategic Plan Advancement: CEO Patrick Lockwood-Taylor stated that this transaction marks an important milestone in the execution of the company's Three-S plan, which aims to stabilize, streamline, and strengthen the company by sharpening its focus on core categories and enhancing competitive advantages.
See More
